Literature DB >> 25412073

Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy.

Liz O'Donovan1, Itaru Okamoto, Andrey A Arzumanov, Donna L Williams, Peter Deuss, Michael J Gait.   

Abstract

We describe two new methods of parallel chemical synthesis of libraries of peptide conjugates of phosphorodiamidate morpholino oligonucleotide (PMO) cargoes on a scale suitable for cell screening prior to in vivo analysis for therapeutic development. The methods represent an extension of the SELection of PEPtide CONjugates (SELPEPCON) approach previously developed for parallel peptide-peptide nucleic acid (PNA) synthesis. However, these new methods allow for the utilization of commercial PMO as cargo with both C- and N-termini unfunctionalized. The synthetic methods involve conjugation in solution phase, followed by rapid purification via biotin-streptavidin immobilization and subsequent reductive release into solution, avoiding the need for painstaking high-performance liquid chromatography purifications. The synthesis methods were applied for screening of PMO conjugates of a 16-member library of variants of a 10-residue ApoE peptide, which was suggested for blood-brain barrier crossing. In this work the conjugate library was tested in an exon skipping assay using skeletal mouse mdx cells, a model of Duchene's muscular dystrophy where higher activity peptide-PMO conjugates were identified compared with the starting peptide-PMO. The results demonstrate the power of the parallel synthesis methods for increasing the speed of optimization of peptide sequences in conjugates of PMO for therapeutic screening.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25412073      PMCID: PMC4296749          DOI: 10.1089/nat.2014.0512

Source DB:  PubMed          Journal:  Nucleic Acid Ther        ISSN: 2159-3337            Impact factor:   5.486


  26 in total

1.  Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.

Authors:  Hong M Moulton; Jon D Moulton
Journal:  Biochim Biophys Acta       Date:  2010-02-17

2.  Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.

Authors:  Bo Wu; Hong M Moulton; Patrick L Iversen; Jiangang Jiang; Juan Li; Jianbin Li; Christopher F Spurney; Arpana Sali; Alfredo D Guerron; Kanneboyina Nagaraju; Timothy Doran; Peijuan Lu; Xiao Xiao; Qi Long Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

3.  Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development.

Authors:  S H Kang; M J Cho; R Kole
Journal:  Biochemistry       Date:  1998-05-05       Impact factor: 3.162

4.  Eteplirsen for the treatment of Duchenne muscular dystrophy.

Authors:  Jerry R Mendell; Louise R Rodino-Klapac; Zarife Sahenk; Kandice Roush; Loren Bird; Linda P Lowes; Lindsay Alfano; Ann Maria Gomez; Sarah Lewis; Janaiah Kota; Vinod Malik; Kim Shontz; Christopher M Walker; Kevin M Flanigan; Marco Corridore; John R Kean; Hugh D Allen; Chris Shilling; Kathleen R Melia; Peter Sazani; Jay B Saoud; Edward M Kaye
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

5.  Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice.

Authors:  HaiFang Yin; Amer F Saleh; Corinne Betts; Patrizia Camelliti; Yiqi Seow; Shirin Ashraf; Andrey Arzumanov; Suzan Hammond; Thomas Merritt; Michael J Gait; Matthew Ja Wood
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

6.  Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor.

Authors:  C A Dyer; D P Cistola; G C Parry; L K Curtiss
Journal:  J Lipid Res       Date:  1995-01       Impact factor: 5.922

Review 7.  A chemical view of oligonucleotides for exon skipping and related drug applications.

Authors:  Peter Järver; Liz O'Donovan; Michael J Gait
Journal:  Nucleic Acid Ther       Date:  2013-10-30       Impact factor: 5.486

8.  Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies.

Authors:  Rachida Abes; Hong M Moulton; Philippe Clair; Sung-Tae Yang; Said Abes; Kamran Melikov; Paul Prevot; Derek S Youngblood; Patrick L Iversen; Leonid V Chernomordik; Bernard Lebleu
Journal:  Nucleic Acids Res       Date:  2008-09-16       Impact factor: 16.971

9.  Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry.

Authors:  Fazel Shabanpoor; Michael J Gait
Journal:  Chem Commun (Camb)       Date:  2013-11-11       Impact factor: 6.222

10.  Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment.

Authors:  Corinne Betts; Amer F Saleh; Andrey A Arzumanov; Suzan M Hammond; Caroline Godfrey; Thibault Coursindel; Michael J Gait; Matthew Ja Wood
Journal:  Mol Ther Nucleic Acids       Date:  2012-08-14       Impact factor: 10.183

View more
  9 in total

Review 1.  "Clicking" Gene Therapeutics: A Successful Union of Chemistry and Biomedicine for New Solutions.

Authors:  Kira Astakhova; Roslyn Ray; Maria Taskova; Jesper Uhd; Annika Carstens; Kevin Morris
Journal:  Mol Pharm       Date:  2018-02-26       Impact factor: 4.939

2.  Synthesis, Characterization, and Function of an RNA-Based Transfection Reagent.

Authors:  Harsh V Jain; Jessica F Boehler; Kanneboyina Nagaraju; Serge L Beaucage
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2018-03

Review 3.  Biotherapeutic effect of cell-penetrating peptides against microbial agents: a review.

Authors:  Idris Zubairu Sadiq; Aliyu Muhammad; Sanusi Bello Mada; Bashiru Ibrahim; Umar Aliyu Umar
Journal:  Tissue Barriers       Date:  2021-10-25

Review 4.  DNA and RNA derivatives to optimize distribution and delivery.

Authors:  Eric Wickstrom
Journal:  Adv Drug Deliv Rev       Date:  2015-04-22       Impact factor: 15.470

5.  An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes.

Authors:  H V Jain; J F Boehler; D Verthelyi; K Nagaraju; S L Beaucage
Journal:  RSC Adv       Date:  2017-09-04       Impact factor: 3.361

6.  An Amphipathic trans-Acting Phosphorothioate DNA Element Delivers Uncharged PNA and PMO Nucleic Acid Sequences in Mammalian Cells.

Authors:  Harsh V Jain; Serge L Beaucage
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2016-03

7.  Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD).

Authors:  Eugénie Ansseau; Céline Vanderplanck; Armelle Wauters; Scott Q Harper; Frédérique Coppée; Alexandra Belayew
Journal:  Genes (Basel)       Date:  2017-03-03       Impact factor: 4.096

Review 8.  Delivery of therapeutic oligonucleotides with cell penetrating peptides.

Authors:  Prisca Boisguérin; Sébastien Deshayes; Michael J Gait; Liz O'Donovan; Caroline Godfrey; Corinne A Betts; Matthew J A Wood; Bernard Lebleu
Journal:  Adv Drug Deliv Rev       Date:  2015-03-04       Impact factor: 15.470

9.  A flow platform for degradation-free CuAAC bioconjugation.

Authors:  Marine Z C Hatit; Linus F Reichenbach; John M Tobin; Filipe Vilela; Glenn A Burley; Allan J B Watson
Journal:  Nat Commun       Date:  2018-10-01       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.